Frontiers in Pharmacology (Feb 2023)
Corrigendum: Therapeutic potential of topical administration of acriflavine against hypoxia-inducible factors for corneal fibrosis
- Shuyan Zhu,
- Huimin Shan,
- Jianqiao Li,
- Lijie Pan,
- Shudan Wang,
- Jing Zhu,
- Hui Guo,
- Fenghua Mi,
- Xinyi Wu,
- Jia Yin,
- Kunpeng Pang
Affiliations
- Shuyan Zhu
- Xi’an People’s Hospital (Xi’an Fourth Hospital), Shanxi Eye Hospital, Xi’an, China
- Huimin Shan
- Department of Ophthalmology, Qilu Hospital of Shandong University, Jinan, Shandong, China
- Jianqiao Li
- Department of Ophthalmology, Qilu Hospital of Shandong University, Jinan, Shandong, China
- Lijie Pan
- Department of Ophthalmology, Qilu Hospital of Shandong University, Jinan, Shandong, China
- Shudan Wang
- Department of Ophthalmology, Harvard Medical School, Schepens Eye Research Institute of Massachusetts Eye and Ear, Boston, MA, United States
- Jing Zhu
- Department of Ophthalmology, Qilu Hospital of Shandong University, Jinan, Shandong, China
- Hui Guo
- Department of Ophthalmology, Qilu Hospital of Shandong University, Jinan, Shandong, China
- Fenghua Mi
- Department of Ophthalmology, Qilu Hospital of Shandong University, Jinan, Shandong, China
- Xinyi Wu
- Department of Ophthalmology, Qilu Hospital of Shandong University, Jinan, Shandong, China
- Jia Yin
- Department of Ophthalmology, Harvard Medical School, Schepens Eye Research Institute of Massachusetts Eye and Ear, Boston, MA, United States
- Kunpeng Pang
- Department of Ophthalmology, Qilu Hospital of Shandong University, Jinan, Shandong, China
- DOI
- https://doi.org/10.3389/fphar.2023.1161682
- Journal volume & issue
-
Vol. 14
Abstract
No abstracts available.Keywords
